Paulus Kirchhof, Ameet Bakhai, Carlo de Asmundis, Joris R de Groot, Jean Claude Deharo, Peter Kelly, Esteban Lopez-de-Sa, Pedro Monteiro, Eva-Maria Fronk, Mathias Lamparter, Petra Laeis, Rüdiger Smolnik, Jan Steffel, Johannes Waltenberger, Thomas W Weiss, Raffaele De Caterina
BACKGROUND: To assess long-term effectiveness and safety of edoxaban in Europe. METHODS AND RESULTS: ETNA-AF-Europe, a prospective, multinational, multi-centre, post-authorisation, observational study was conducted in agreement with the European Medicines Agency. The primary and secondary objectives assessed real-world safety (including bleeding and deaths) and effectiveness (including stroke, systemic embolic events and clinical edoxaban use), respectively. Median (interquartile range) age of the 13,164 patients was 75...
April 30, 2024: International Journal of Cardiology